|
Deterministic
|
|
Ribociclib
|
Modelled PFS at
1 year: 74.6%
2 years: 56.3%
5 years: 24.2%
40 years: 0.0%
Modelled OS at
1 year: 96.7%
2 years: 87.1%
5 years: 39.5%
40 years: 0.0%
|
Total: £104 230
Acquisition: £58 358
Drug monitoring: £602
Drug-wastage: £0
PFS costs: £17 179
PD costs: £20 466
Subs. therapy costs: £4201
Terminal care: £3 266
AE: £157
|
Total: 3.296
PF: 2.673
PD: 0.68
|
Total: -£8464
Acquisition: -£10 166
Drug monitoring: £525
Drug-wastage: -£1482
PFS costs: £1495
PD costs: £1107
Subs. therapy costs: £191
Terminal care: -£44
AE: £85
|
Total: 0.261
PFS: 0.233
PD: 0.028
|
Ribociclib is dominant |
|
|
|
|
|
| Palbociclib |
Modelled PFS at
1 year: 72.3%
2 years: 52.9%
5 years: 20.7%
40 years: 0.0%
Modelled OS at
1 year: 96.1%
2 years: 84.8%
5 years: 33.1%
40 years: 0.0%
|
Total: £112 694
Acquisition: £68 524
Drug monitoring: £77
Drug-wastage: £1482
PFS costs: £15 684
PD costs: £19 535
Subs. therapy costs: £4010
Terminal care: £3310
AE: £72
|
Total: 3.034
PF: 2.673
PD: 0.68
|
|
|
|
|
|
|
|
| Probabilistic |
| Ribociclib |
NE |
£107 740
(95% CI: £107 265, £108 214)
|
3.404
(95% CI: 3.389, 3.418)
|
-£7914 |
0.273 |
Ribociclib is dominant |
|
|
|
| Palbociclib |
NE |
£115 654
(95% CI: £115 134, £116 173)
|
3.130
(95% CI: 3.116, 3.144)
|
|
|
|
|
|